Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President...
Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global...
The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and refinement of state-of-the-art ML-ready disease models and integration with...
Sponsored programming featuring commercials from Synergy CHC (NASDAQ:SNYR), HelloAxel.com (private), The Sustainable Green Team (OTC:SGTM - Waterless Garden), DataVault AI (NASDAQ:DVLT), and PetVivo (OTCQX:PETV)....
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights...
Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary...
Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in...
Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a...
• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across...
NEW YORK CITY, NEW YORK / ACCESS Newswire / November 8, 2025 / New to The Street announces the broadcast of Show Number 698, airing on Bloomberg Television this Saturday, November 8, 2025, at 6:30 PM EST,...